3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Neoplasms
7
Infections
7
Prostatic Neoplasms
4
Neutropenia
4
Lymphoma
4
Leukemia
4
Neoplasms, Plasma Cell
3
Febrile Neutropenia
3
Urinary Tract Infections
2
Pancreatic Neoplasms
2
Pancreatic Cyst
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myeloid, Acute
2
Hematologic Neoplasms
2
Staphylococcal Infections
1
Squamous Cell Carcinoma of Head and Neck
1
Spasm
1
Sleep Initiation and Maintenance Disorders
1
Sepsis
1
Seizures
1
Schizophrenia, Treatment-Resistant
1
Schizophrenia
1
Retinitis
1
Renal Insufficiency, Chronic
1
Recurrence
1
Rectal Neoplasms
1
Pulmonary Arterial Hypertension
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pneumonia
1
Pain
1
Interventions
Radiosurgery
3
Filgrastim
2
pegfilgrastim
1
Paclitaxel
1
DAT protocol 1
1
Ciprofloxacin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Early Stage Breast Cancer
×
Ciprofloxacin
×
Clear all
NCT02816112
2020-05-27
REaCT-TC2
Ottawa Hospital Research Institute
Phase 4
Completed
458 enrolled